OBJECTIVES: In joint degenerative diseases, the collagens are degraded by matrix metalloproteinases and protein fragments are released to serum as potential biomarkers. METHODS: A collagen type II specific neoepitope, CIIM, was identified (…RDGAAG(1053)) by mass spectrometry. Two ELISAs against the neoepitope were developed. CIIM was measured in cartilage explants in the presence or absence of protease inhibitors. CIIM was measured in OA synovial fluid (n=51) and serum (n=156). Knee OA was graded by standard Kellgren-Lawrence (KL) score. RESULTS: The ELISAs showed good technical performance; CV%, <13%. CIIM release from cartilage explants was blocked by the MMP inhibitor. CIIM was detected in synovial fluid. Furthermore, serum CIIM levels were significantly higher (P<0.05) in those individuals with mild or severe OA than in those with no OA. CONCLUSION: We developed a new biomarker for joint degenerative diseases, which we demonstrated was derived from MMP-degraded type II collagen.
OBJECTIVES: In joint degenerative diseases, the collagens are degraded by matrix metalloproteinases and protein fragments are released to serum as potential biomarkers. METHODS: A collagen type II specific neoepitope, CIIM, was identified (…RDGAAG(1053)) by mass spectrometry. Two ELISAs against the neoepitope were developed. CIIM was measured in cartilage explants in the presence or absence of protease inhibitors. CIIM was measured in OA synovial fluid (n=51) and serum (n=156). Knee OA was graded by standard Kellgren-Lawrence (KL) score. RESULTS: The ELISAs showed good technical performance; CV%, <13%. CIIM release from cartilage explants was blocked by the MMP inhibitor. CIIM was detected in synovial fluid. Furthermore, serum CIIM levels were significantly higher (P<0.05) in those individuals with mild or severe OA than in those with no OA. CONCLUSION: We developed a new biomarker for joint degenerative diseases, which we demonstrated was derived from MMP-degraded type II collagen.
Authors: Anne C Bay-Jensen; Diana J Leeming; Arndt Kleyer; Sanne S Veidal; Georg Schett; Morten A Karsdal Journal: Rheumatol Int Date: 2011-11-16 Impact factor: 2.631
Authors: Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White Journal: J Invest Dermatol Date: 2015-05-20 Impact factor: 8.551
Authors: F Genovese; A S Siebuhr; K Musa; J A Gallagher; A M Milan; M A Karsdal; J Rovensky; A C Bay-Jensen; L R Ranganath Journal: JIMD Rep Date: 2015-03-19
Authors: Heidi Lausten Munk; Natasja Staehr Gudmann; Anne Friesgaard Christensen; Leif Ejstrup; Grith Lykke Sorensen; Anne Gitte Loft; Anne C Bay-Jensen; Anne Sofie Siebuhr; Peter Junker Journal: Rheumatol Int Date: 2015-11-30 Impact factor: 2.631
Authors: Helene Skjøt-Arkil; Rikke E Clausen; Lars M Rasmussen; Wanchun Wang; Yaguo Wang; Qinlong Zheng; Hans Mickley; Lotte Saaby; Axel C P Diederichsen; Jess Lambrechtsen; Fernando J Martinez; Cory M Hogaboam; Meilan Han; Martin R Larsen; Arkadiusz Nawrocki; Ben Vainer; Dorrit Krustrup; Marina Bjørling-Poulsen; Morten A Karsdal; Diana J Leeming Journal: PLoS One Date: 2013-06-21 Impact factor: 3.240